AstraZeneca submitted a market application for the injectable drug Tremelimumab.

Nurix Therapeutics unveiled promising data from its Phase 1a/1b clinical trial of NX-5948 at the 12th International Workshop on Waldenstrom's Macroglobulinemia.

In the development of antibody-drug conjugates (ADCs), selecting an appropriate linker is a critical factor that determines the efficacy and safety of the final product.

A recent review in the journal Nature Reviews Clinical Oncology has explored new therapeutic approaches for multiple myeloma (MM) targeting cell membrane proteins.

Hiro-LS, PatSnap's biopharmaceutical AI model, integrates the proprietary PharmaGPT, a large-scale AI model with 70 billion parameters.

the Danish pharmaceutical company Zealand Pharma announced clinical Phase 1 data for its long-acting amylin analogue, Petrelintide, which is being studied for weight management.

Amylin is a pancreatic peptide consisting of 37 amino acids that is co-stored and co-secreted with insulin in response to nutrient intake.

On September 19, 2024, the NMPA accepted Hengrui Pharmaceutical's marketing authorization application for the Class 1 new drug Retlirafusp-α Injection (SHR-1701).

Recently, Innovent Biologics announced promising clinical results for their potential first-in-class dual-specific antibody fusion protein targeting PD-1 and IL-2 (IBI363).

On September 11, 2024, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for the treatment of moderate to severe active ulcerative colitis (UC).

On September 11, 2024, Sanofi and Regeneron jointly announced that their pivotal study (ADEPT) of Dupilumab (Dupixent) for the treatment of adult patients with Bullous Pemphigoid (BP).

KaliVir is able to produce novel, potent oncolytic Vaccinia viruses with high replication ability and enhanced capabilities for intravenous administration and dissemination.